LeMaitre price target raised to $27 from $24 at Lake Street

Lake Street analyst Brooks O’Neil raised his price target for LeMaitre Vascular to $27 saying the company reported “solid” Q4 results as RestoreFlow and Valvulotomes recovered from Q3. However, management does not appear ready to suggest 10% sales and 20% earnings growth “are again in focus,” O’Neil tells investors in a post-earnings research note. He keeps a Hold rating on LeMaitre.
https://thefly.com/landingPageNews.php?id=2866963